Pexidartinib: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

8 December 2024

  • curprev 17:5517:55, 8 December 2024 Omid Afkhami-Ardakani talk contribs 5,904 bytes +5,904 Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pexidartinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Tenosynovial Giant Cell Tumor (TGCT). |hasBlackBoxWarning=Yes |adverseReactions=Increased liver enzymes (e.g., AST, ALT), Hair color changes, Increased cholesterol levels, Decreased white blood cell counts, Fatigue, Edema, Rash, and Dysgeusia (altered taste). Decreased phosphate levels |blackBoxWarning..."